Oncoclinicas do Brasil (ONCO3) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.127x

Based on the latest financial reports, Oncoclinicas do Brasil (ONCO3) has a cash flow conversion efficiency ratio of 0.127x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (R$151.75 Million ≈ $29.78 Million USD) by net assets (R$1.20 Billion ≈ $235.17 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Oncoclinicas do Brasil for the company's overall valuation and market capitalisation.

Oncoclinicas do Brasil - Cash Flow Conversion Efficiency Trend (2013–2024)

This chart illustrates how Oncoclinicas do Brasil's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Oncoclinicas do Brasil Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Oncoclinicas do Brasil ranked by their cash flow conversion efficiency. Explore ONCO3 operating cash flow to net income to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
VAA Vista Alegre Atlantis SGPS SA
LS:VAF
0.061x
Firm Capital Property Trust
TO:FCD-UN
0.031x
Deo Ca Traffic Infrastructure Investment JSC
VN:HHV
0.009x
Gwangjushinseg
KO:037710
0.039x
P2 Gold Inc
V:PGLD
-0.511x
Gofore Oyj
HE:GOFORE
-0.013x
Asian Sea Corporation Public Company Limited
BK:ASIAN
0.060x
Steel Pipe Industry Of Indonesia
JK:ISSP
0.086x

Annual Cash Flow Conversion Efficiency for Oncoclinicas do Brasil (2013–2024)

The table below shows the annual cash flow conversion efficiency of Oncoclinicas do Brasil from 2013 to 2024. View Oncoclinicas do Brasil (ONCO3) stock price for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 R$3.38 Billion
≈ $663.69 Million
R$-184.85 Million
≈ $-36.27 Million
-0.055x -183.98%
2023-12-31 R$2.68 Billion
≈ $525.74 Million
R$-51.56 Million
≈ $-10.12 Million
-0.019x +81.35%
2022-12-31 R$2.63 Billion
≈ $516.54 Million
R$-271.64 Million
≈ $-53.30 Million
-0.103x -2462.19%
2021-12-31 R$2.30 Billion
≈ $452.27 Million
R$-9.28 Million
≈ $-1.82 Million
-0.004x -102.81%
2020-12-31 R$681.17 Million
≈ $133.66 Million
R$97.56 Million
≈ $19.14 Million
0.143x -3.16%
2019-12-31 R$656.37 Million
≈ $128.79 Million
R$97.08 Million
≈ $19.05 Million
0.148x +78.93%
2018-12-31 R$470.12 Million
≈ $92.25 Million
R$38.86 Million
≈ $7.62 Million
0.083x -85.80%
2017-12-31 R$232.44 Million
≈ $45.61 Million
R$135.26 Million
≈ $26.54 Million
0.582x +787.30%
2016-12-31 R$244.56 Million
≈ $47.99 Million
R$-20.71 Million
≈ $-4.06 Million
-0.085x -435.49%
2015-12-31 R$195.87 Million
≈ $38.43 Million
R$-3.10 Million
≈ $-607.69K
-0.016x -103.88%
2014-12-31 R$22.77 Million
≈ $4.47 Million
R$9.29 Million
≈ $1.82 Million
0.408x +167.53%
2013-12-31 R$48.16 Million
≈ $9.45 Million
R$7.34 Million
≈ $1.44 Million
0.152x --

About Oncoclinicas do Brasil

SA:ONCO3 Brazil Medical Care Facilities
Market Cap
$181.01 Million
R$922.52 Million BRL
Market Cap Rank
#17015 Global
#163 in Brazil
Share Price
R$1.05
Change (1 day)
-1.87%
52-Week Range
R$0.55 - R$3.72
All Time High
R$19.24
About

Oncoclínicas do Brasil Serviços Médicos S.A., together with its subsidiaries, provides oncology, hematology, radiotherapy, and genomics healthcare services in Latin America. The company offers treatment services, including radiotherapy, hormone therapy, immunotherapy, port-a-cath, palliative care, target therapy, breast cancer hormone therapy, bone marrow transplant, non-oncological infusions, ch… Read more